Addex Therapeutics

296 articles about Addex Therapeutics

• Addex Convenes Extraordinary General Meeting

  11/28/2023

  Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that an Extraordinary General Meeting is convened and will take place on Tuesday December 19, 2023, at 11:00 am CET at the Campus Biotech, Chemin des Mines 9, 1202 Geneva.

• Addex Therapeutics to Release Third Quarter 2023 Financial Results and Host Conference Call on November 29, 2023

  11/23/2023

  Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that that it will issue its Third Quarter 2023 Financial Results on November 29, 2023.

• Addex ADX71149 Epilepsy Phase 2 Study Completes Recruitment of Patients

  11/14/2023

  Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that the last patient has been randomized in Cohort 2 of the ADX71149 Phase 2 epilepsy clinical study.

• Addex Regains Nasdaq Listing Compliance

  11/8/2023

  Addex Therapeutics announced it had received written notification from The Nasdaq Stock Market LLC that it has regained compliance with the minimum bid price requirement of $1.00 per ADS under Nasdaq Listing Rule 5550 and currently meets all other applicable criteria for continued listing.

• Addex Announces Participation in the Bio-Europe 2023 Conference

  11/2/2023

  Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that Tim Dyer, Chief Executive Officer, and Dr. Mikhail Kalinichev, Head of Translational Science, will be attending the Bio-Europe 2023 Conference in Munich, Germany.

• Addex Announces Plan to Implement ADS Ratio Change

  10/6/2023

  Addex Therapeutics announced that it plans to change the ratio of its American Depositary Shares to its ordinary shares from the current ADS Ratio of one ADS to six ordinary shares to a new ADS Ratio of one ADS to one hundred and twenty ordinary shares.

• Addex mGlu2 NAM Cognition Program Receives €4 Million Grant

  9/20/2023

  Addex Therapeutics announced that it has led a consortium which has been awarded a €4 million Eurostars grant to support its metabotropic glutamate 2 receptor negative allosteric modulator program for mild neurocognitive disorder.

• 

  As Impact of Substance Use Disorders Rise, So Do Innovative Solutions

  9/18/2023

  From reversing overdose to blocking cravings, the biopharma industry is looking at a range of possible solutions to addiction.

• Addex Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference

  9/6/2023

  Addex Therapeutics announced that Tim Dyer, Chief Executive Officer, will be attending the H.C. Wainwright 25th Annual Global Investment Conference in New York.

• Addex ADX71149 Phase 2 Epilepsy Study Expected to Readout Data in Q2 2024

  9/5/2023

  Addex Therapeutics announced that the ADX71149 Phase 2 epilepsy clinical study is progressing well, with Cohort 1 completed and 80% of patients recruited into Cohort 2.

• Addex Reports 2023 Half Year and Second Quarter Financial Results and Provides Corporate Update

  8/10/2023

  Addex Therapeutics reported its half-year and second quarter financial results for the periods ended June 30, 2023 and provided a corporate update.

• Addex GABAB Positive Allosteric Modulator Program to Receive Additional CHF2.7 Million from Indivior in Extended Substance Use Disorder Research Collaboration

  8/3/2023

  Addex Therapeutics announced that its collaboration agreement with Indivior PLC for the discovery of novel oral gamma-aminobutyric acid subtype B positive allosteric modulator drug candidates for the treatment of substance use disorder has been extended until June 30, 2024.

• Addex Reports Q1 2023 Financial Results and Provides Corporate Update

  5/11/2023

  Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the first quarter ended March 31, 2023, and provided a corporate update.

• Addex Announces ADX71149 Phase 2 Epilepsy Clinical Study’s Independent Interim Review Committee Recommends Continuing Study

  5/10/2023

  Addex Therapeutics announced that the ADX71149 Phase 2 epilepsy clinical study has been recommended to continue by an Independent Interim Review Committee following review of unblinded data from Part 1 of patient Cohort 1.

• Addex Therapeutics to Release Q1 2023 Financial Results and Host Conference Call on May 11, 2023

  5/4/2023

  Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that it will issue its Q1 2023 financial results on Thursday, May 11, 2023.

• Addex Completes $5.0 Million Equity Financing

  4/5/2023

  Addex Therapeutics Ltd announced that it has completed the equity financing transaction entered into on April 3, 2023 with a leading institutional healthcare investor, pursuant to which the Company sold 7,999,998 shares in the form of 1,333,333 American Depositary Shares at a gross purchase price of $0.95 per ADS.

• Addex Publishes Dipraglurant Data Showing In Vivo Efficacy on Motor and Non-Motor Symptoms of Parkinson’s Disease

  4/4/2023

  Addex Therapeutics announced data showing that dipraglurant could have beneficial effects on non-motor symptoms experienced by Parkinson’s patients in addition to its established positive effects on dyskinesias.

• Addex Reports Full Year 2022 Financial Results and Provides Corporate Update

  3/30/2023

  Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported financial results for the full-year ended December 31, 2022, and provided a corporate update.

• Addex Therapeutics to Release Full-Year 2022 Financial Results and Host Conference Call on March 30, 2023

  3/28/2023

  Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced that it will issue its full-year 2022 financial results on Thursday, March 30, 2023.

• Addex Announces Upcoming Conferences it will participate for H1 2023

  3/16/2023

  Addex Therapeutics Ltd announced that it will participate in the following conferences during the first half of 2023.